Draft Health Technology Assessment of COVID-19 Vaccination in Ireland (hiqa.ie)

• HIQA draft HTA on COVID-19 vaccination published 29 June 2026.
• COVID-19 burden declining but high in over-80s; 260 deaths in 2025.
• Twice-yearly vaccination of 80+ cost-effective only if vaccine price ≤€60/dose.
• Vaccine uptake declining; communication strategy needed for any eligibility changes.

"HIQA published a draft HTA on COVID-19 vaccination in Ireland (June 29, 2026). Key findings: COVID-19 burden decreased but remains high among older adults; vaccination uptake declined since September 2023; vaccines are safe and effective but protection wanes; at €75/dose, twice-yearly vaccination of 80+ would cost €112m over 5 years and is not cost-effective, but at €60/dose it becomes cost-effective. The HTA will inform Department of Health decisions on prioritisation for 2027/2028."